This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) (OSKIRA -4)

This study has been terminated.
(AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.)
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01264770
First received: December 17, 2010
Last updated: April 3, 2014
Last verified: April 2014
Results First Received: November 22, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib and placebo injections
Drug: Adalimumab and placebo of fostamatinib
Drug: Placebo of fostamatinib, fostamatinib, and placebo injections

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
452 patients were enrolled into the main study, with 198 patients enrolled into a separate MRI sub-study. Synovitis results for the MRI sub-study were reported later due to study delays and so are presented entirely separately.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 173 patients failed screening to the main study.

Reporting Groups
  Description
FOSTA 100 MG BID PO Dosing Group A
FOSTA 100 MG BID (4 WKS) THEN 150 MG QD PO Dosing Group B
FOSTA 100 MG BID (4 WKS) THEN 100 MG QD PO Dosing Group C
ADALIMUMAB 40 MG SC Dosing Group D
PLACEBO (6 WKS) THEN FOSTA 100 MG BID PO Dosing Group F
PLACEBO (6 WK) THEN FOSTA 100 MG BID (4 WK) THEN 150 MG QD PO Dosing Group G

Participant Flow:   Overall Study
    FOSTA 100 MG BID PO   FOSTA 100 MG BID (4 WKS) THEN 150 MG QD PO   FOSTA 100 MG BID (4 WKS) THEN 100 MG QD PO   ADALIMUMAB 40 MG SC   PLACEBO (6 WKS) THEN FOSTA 100 MG BID PO   PLACEBO (6 WK) THEN FOSTA 100 MG BID (4 WK) THEN 150 MG QD PO
STARTED   54 [1]   48 [1]   57 [1]   54 [1]   27 [1]   25 [1] 
Randomised But Did Not Receive Treatment   2 [2]   5 [2]   2 [2]   3 [2]   2 [2]   0 [2] 
COMPLETED   36 [3]   38 [3]   41 [3]   48 [3]   19 [3]   19 [3] 
NOT COMPLETED   18   10   16   6   8   6 
Not reported                0                0                1                0                0                0 
e.g., change in circumstances                8                3                3                3                4                4 
Severe non-compliance to protocol                0                0                1                1                0                0 
Lack of therapeutic response                1                0                2                1                1                0 
Dev. of study specific discont. criteria                2                0                0                0                1                1 
Lost to Follow-up                0                0                1                1                0                0 
Adverse Event                7                7                8                0                2                1 
[1] Patients who received treatment
[2] Eligibility criteria not fulfilled/subject decision/other
[3] Number of patients who completed treatment includes patients who had a dose reduction.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
FOSTA 100 MG BID PO Dosing Group A
FOSTA 100 MG BID (4 WKS) THEN 150 MG QD PO Dosing Group B
FOSTA 100 MG BID (4 WKS) THEN 100 MG QD PO Dosing Group C
ADALIMUMAB 40 MG SC Dosing Group D
PLACEBO (6 WKS) THEN FOSTA 100 MG BID PO Dosing Group F
PLACEBO (6 WK) THEN FOSTA 100 MG BID (4 WK) THEN 150 MG QD PO Dosing Group G
Total Total of all reporting groups

Baseline Measures
   FOSTA 100 MG BID PO   FOSTA 100 MG BID (4 WKS) THEN 150 MG QD PO   FOSTA 100 MG BID (4 WKS) THEN 100 MG QD PO   ADALIMUMAB 40 MG SC   PLACEBO (6 WKS) THEN FOSTA 100 MG BID PO   PLACEBO (6 WK) THEN FOSTA 100 MG BID (4 WK) THEN 150 MG QD PO   Total 
Overall Participants Analyzed 
[Units: Participants]
 54   48   57   54   27   25   265 
Age 
[Units: Years]
Mean (Standard Deviation)
 50  (11.5)   50  (12.6)   50  (11.0)   48  (12.4)   50  (12.7)   53  (10.8)   50  (11.8) 
Gender 
[Units: Participants]
             
Female   38   39   48   45   20   20   210 
Male   16   9   9   9   7   5   55 
Race/Ethnicity, Customized 
[Units: Participants]
             
White   48   47   48   51   23   23   240 
Black or African American   5   0   6   1   3   1   16 
Asian   1   1   0   1   0   1   4 
American Indian or Alaska Native   0   0   1   0   0   0   1 
Indian or Pakistani   0   0   1   1   0   0   2 
Other   0   0   1   0   1   0   2 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   DAS28-CRP Score - Change From Baseline to Week 6 Compared to Placebo   [ Time Frame: Baseline and 6 weeks ]

2.  Primary:   DAS28-CRP Score - Change From Baseline to Week 24 Compared to Adalimumab   [ Time Frame: Baseline and 24 weeks ]

3.  Secondary:   DAS28 EULAR Response at Week 6   [ Time Frame: 6 weeks ]

4.  Secondary:   DAS28 EULAR Response at Week 24   [ Time Frame: 24 weeks ]

5.  Secondary:   Proportion of Patients Achieving ACR20 up to Week 24   [ Time Frame: 6 and 24 weeks ]

6.  Secondary:   Proportion of Patients Achieving ACR50 up to Week 24   [ Time Frame: 6 and 24 weeks ]

7.  Secondary:   Proportion of Patients Achieving ACR70 up to Week 24   [ Time Frame: 6 and 24 weeks ]

8.  Secondary:   ACRn - Comparison Between Fostamatinib and Placebo at Week 6   [ Time Frame: Baseline and 6 weeks ]

9.  Secondary:   ACRn - Comparison Between Fostamatinib and Adalimumab at Week 24   [ Time Frame: Baseline and 24 weeks ]

10.  Secondary:   HAQ-DI - Comparison of the Change From Baseline Between Fostamatinib and Placebo at Week 6   [ Time Frame: Baseline and 6 weeks ]

11.  Secondary:   HAQ-DI - Comparison of the Change From Baseline Between Fostamatinib and Adalimumab at Week 24   [ Time Frame: Baseline and 24 weeks ]

12.  Secondary:   SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Adalimumab at Week 24   [ Time Frame: Baseline and 24 weeks ]

13.  Secondary:   SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Adalimumab at Week 24   [ Time Frame: Baseline and 24 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Dave Goldstraw
Organization: AstraZeneca Pharmaceuticals
phone: +44 (0)1625 512415
e-mail: dave.goldstraw@astrazeneca.com


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01264770     History of Changes
Other Study ID Numbers: D4300C00004
2010-023692-26 ( EudraCT Number )
Study First Received: December 17, 2010
Results First Received: November 22, 2013
Last Updated: April 3, 2014